Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential

Show simple item record

dc.contributor.author Schnider, Jonas T.
dc.contributor.author Weinstock, Matthias [UNIFESP]
dc.contributor.author Plock, Jan A.
dc.contributor.author Solari, Mario G.
dc.contributor.author Venkataramanan, Raman
dc.contributor.author Zheng, Xin Xiao
dc.contributor.author Gorantla, Vijay S.
dc.date.accessioned 2016-01-24T14:30:53Z
dc.date.available 2016-01-24T14:30:53Z
dc.date.issued 2013-01-01
dc.identifier http://dx.doi.org/10.1155/2013/495212
dc.identifier.citation Clinical & Developmental Immunology. New York: Hindawi Publishing Corporation, 7 p., 2013.
dc.identifier.issn 1740-2522
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/35693
dc.description.abstract Skin is the most immunogenic component of a vascularized composite allograft (VCA) and is the primary trigger and target of rejection. the skin is directly accessible for visual monitoring of acute rejection (AR) and for directed biopsy, timely therapeutic intervention, and management of AR. Logically, antirejection drugs, biologics, or other agents delivered locally to the VCA may reduce the need for systemic immunosuppression with its adverse effects. Topical FK 506 (tacrolimus) and steroids have been used in clinical VCA as an adjunct to systemic therapy with unclear beneficial effects. However, there are no commercially available topical formulations for other widely used systemic immunosuppressive drugs such as mycophenolic acid, sirolimus, and everolimus. Investigating the site-specific therapeutic effects and efficacy of systemically active agents may enable optimizing the dosing, frequency, and duration of overall immunosuppression in VCA with minimization or elimination of long-term drug-related toxicity. en
dc.description.sponsorship Swiss National Science Foundation
dc.format.extent 7
dc.language.iso eng
dc.publisher Hindawi Publishing Corporation
dc.relation.ispartof Clinical & Developmental Immunology
dc.rights Acesso aberto
dc.title Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential en
dc.type Resenha
dc.contributor.institution Univ Pittsburgh
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Univ Zurich Hosp
dc.contributor.institution Tongji Univ
dc.contributor.institution Dept Plast Surg
dc.description.affiliation Univ Pittsburgh, Sch Med, Dept Plast & Reconstruct Surg, Pittsburgh, PA 15261 USA
dc.description.affiliation Universidade Federal de São Paulo, Escola Paulista Med, Disciplina Cirurgia Plast, BR-04024900 São Paulo, Brazil
dc.description.affiliation Univ Zurich Hosp, Div Plast & Hand Surg, CH-8091 Zurich, Switzerland
dc.description.affiliation Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
dc.description.affiliation Tongji Univ, Shanghai East Hosp, Res Ctr Translat Med, Shanghai 200120, Peoples R China
dc.description.affiliation Dept Plast Surg, Pittsburgh Reconstruct Transplantat Program, Pittsburgh, PA 15261 USA
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Escola Paulista Med, Disciplina Cirurgia Plast, BR-04024900 São Paulo, Brazil
dc.identifier.file WOS000315256900001.pdf
dc.identifier.doi 10.1155/2013/495212
dc.description.source Web of Science
dc.identifier.wos WOS:000315256900001



File

Name: WOS000315256900001.pdf
Size: 1.213Mb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account